1. Conventional dendritic cells 2, the targeted antigen-presenting-cell, induces enhanced type 1 immune responses in mice immunized with CVC1302 in oil formulation.
- Author
-
Du L, Lu H, Qiao X, Zhang Y, Hou L, Yu X, Cheng H, Chen J, Zheng Q, Hou J, and Tong G
- Subjects
- Animals, Mice, Lymph Nodes immunology, Cell Differentiation drug effects, Ovalbumin immunology, Antigen-Presenting Cells immunology, Antigen-Presenting Cells metabolism, Female, Lymphocyte Activation immunology, Lymphocyte Activation drug effects, Oils chemistry, Mice, Inbred C57BL, Dendritic Cells immunology, Th1 Cells immunology, Cytokines metabolism, Immunization
- Abstract
Multifunctional CD4
+ T helper 1 (Th1) cells, producing IFN-γ, TNF-α and IL-2, define a correlate of vaccine-mediated protection against intracellular infection. In our previous study, we found that CVC1302 in oil formulation promoted the differentiation of IFN-γ+ /TNF-α+ /IL-2+ Th1 cells. In order to extend the application of CVC1302 in oil formulation, this study aimed to elucidate the mechanism of action in improving the Th1 immune response. Considering the signals required for the differentiation of CD4+ T cells to Th1 cells, we detected the distribution of innate immune cells and the model antigen OVA-FITC in lymph node (LN), as well as the quantity of cytokines produced by the innate immune cells. The results of these experiments show that, cDC2 and OVA-FITC localized to interfollicular region (IFR) of the draining lymph nodes, inflammatory monocytes localized to both IFR and T cell zone, which mainly infiltrate from the blood. In this inflammatory niche within LN, CD4+ T cells were attracted into IFR by CXCL10, secreted by inflammatory monocytes, then activated by cDC2, secreting IL-12. Above all, CVC1302 in oil formulation, on the one hand, targeted antigen and inflammatory monocytes into the LN IFR in order to attract CD4+ T cells, on the other hand, targeted cDC2 to produce IL-12 in order to promote optimal Th1 differentiation. The new finding will provide a blueprint for application of immunopotentiators in optimal formulations., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could appear to have influenced the work reported in this paper., (Copyright © 2024 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF